A 2026 systematic review and meta-analysis pooled randomized controlled trials of MDMA-assisted therapy (MDMA-AT) for posttraumatic stress disorder (PTSD), comparing it with control conditions on clinical and functional outcomes. The review searched nine databases plus manual searches through August 14, 2025, and assessed risk of bias with the Cochrane RoB2 tool and certainty with GRADE.
Fourteen studies entered qualitative synthesis and eight trials supplied data for quantitative synthesis. For PTSD symptom severity, the pooled standardized mean difference was -1.19 (95% CI -1.95 to -0.42; 298 participants), with substantial heterogeneity (I² = 68.8%). That standardized scale is not a percentage of people who improved.
Trust is limited. Most studies showed high risk of bias in outcome measurement, some had concerns about deviations from intended intervention, and overall certainty was very low. The abstract reports small samples, heterogeneity, and that most studies lacked active controls, which likely compromised blinding integrity. The abstract does not report how participants were randomized or blinded in individual trials.
A useful question: how much of the pooled symptom-severity estimate would remain if only trials with active controls and low risk of outcome-measurement bias were included? The authors call for larger, higher-quality RCTs with active controls and long-term follow-up.
Review: PMID 41825162 · DOI 10.1016/j.euroneuro.2026.112802
Escribir Únete para participar en la discusión.